Simvastatin and Paclitaxel: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 4, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Simvastatin
Paclitaxel
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed simvastatin (a cholesterol medicine) and paclitaxel (a chemotherapy drug). Both are broken down by the same liver enzyme, called CYP3A4. Because they share this pathway, they can affect how much of each other stays in your body. In theory, this could change how much paclitaxel you're exposed to, which might make its side effects (like low blood counts, nerve tingling, or nausea) either stronger or weaker.
The good news: this concern comes mostly from lab studies, not strong real-world proof. Please don't stop either medicine on your own. Your cancer care team knows how to watch for this and can adjust things safely.
Interaction: Both agents are CYP3A4 substrates; paclitaxel is metabolized to minor metabolites primarily via CYP3A4. Concomitant use may alter paclitaxel exposure (AUC/Cmax), with potential for either reduced efficacy or increased paclitaxel-related toxicity.
- Direction: Variable/altered exposure; documented as reduced effect and/or increased adverse reactions.
- Onset: Delayed.
- Evidence: Theoretical, largely in vitro.
- Severity: Moderate.
Management: Exercise caution with concurrent use. Monitor for paclitaxel toxicity (myelosuppression, peripheral neuropathy, GI effects) and clinical response. Dose can be individualized by the oncology team; consider closer monitoring rather than automatic changes.
What happens
Altered (increased/reduced) PACLitaxel exposure, reduced PACLitaxel exposure and an increased PACLitaxel-related adverse reactions and toxicity
Interaction Deep Dive
Use care when giving PACLitaxel together with CYP3A4 substrates12 [as well as PACLitaxel protein-bound particles for injectable suspension (albumin-bound)] alongside agents identified as CYP3A4 substrates, since taking them together may change PACLitaxel exposure 3. According to in vitro studies, CYP3A4 metabolized PACLitaxel mainly into 2 minor metabolites, namely 3'-p-hydroxyPACLitaxel and 6-alpha, 3'-p-dihydroxyPACLitaxel. In addition, interactions in vivo with compounds that serve as CYP3A4 substrates may modify the pharmacokinetics of PACLitaxel 13.
Why it happens (mechanism)
Inhibition of CYP3A4-substrates metabolism by PACLitaxel; induction of CYP3A4-substrates metabolism by PACLitaxel
How to manage this interaction
This interaction is manageable, and your team plans for it. Here's what typically happens and what you can do:
- Keep taking both exactly as prescribed unless your oncologist or pharmacist tells you otherwise.
- Your care team may monitor you more closely for paclitaxel side effects, such as low blood counts, numbness or tingling in your hands and feet, and nausea.
- Your medication doses may be adjusted and individualized by your care team based on how you respond.
- Tell your pharmacist and doctor about all your medicines, and report new or worsening side effects promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In vitro investigations demonstrated that PACLitaxel underwent metabolism mainly into 2 minor metabolites, 3'-p-hydroxyPACLitaxel and 6-alpha, 3'-p-dihydroxyPACLitaxel, via CYP3A4. In vivo interactions with agents that serve as substrates of CYP3A4 may likewise change the pharmacokinetics of PACLitaxel 13.
Common questions
Can I take Simvastatin and Paclitaxel together?
Simvastatin and paclitaxel share the CYP3A4 liver pathway, which could alter paclitaxel levels and its side effects, though this concern is mainly theoretical. Keep taking both as prescribed and let your care team monitor and adjust as needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Simvastatin and Paclitaxel interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How is the Simvastatin and Paclitaxel interaction managed?
This interaction is manageable, and your team plans for it. Here's what typically happens and what you can do: Keep taking both exactly as prescribed unless your oncologist or pharmacist tells you otherwise. Your care team may monitor you more closely for paclitaxel side effects, such as low blood counts, numbness or tingling in your hands and feet, and nausea. Your medication doses may be adjuste… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Simvastatin or Paclitaxel need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (3)
- Product Information: PACLITAXEL intravenous injection, paclitaxel intravenous injection. Fresenius Kabi (per Dailymed), Lake Zurich, IL, 2024. DailyMed
- Product Information: TAXOL(R) IV injection, paclitaxel IV injection. Bristol-Myers Squibb Company, Princeton, NJ, 2011.
- Product Information: PACLITAXEL PROTEIN-BOUND PARTICLES (ALBUMIN-BOUND) intravenous injection lyophilized powder for suspension, paclitaxel protein-bound particles (albumin-bound) intravenous injection lyophilized powder for suspension. Sandoz Inc (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Simvastatin
Keep reading about Paclitaxel
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist